Transitioning immunotherapy in neuromyelitis optica spectrum disorder – when and how to switch

References

• Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013;10(1):1–12.
   PubMedGoogle Scholar
• Jarius S, Wildemann B. Devic’s disease before Devic: bilateral optic neuritis and simultaneous myelitis in a young woman (1874). J Neurol Sci. 2015;358(1–2):419–421.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–2112.
   PubMed Web of Science ®Google Scholar
• Oh J, Levy M. Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int. 2012;2012:1–13.
   Google Scholar
• Hamid SH, Whittam D, Mutch K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017;264(10):2088–2094.
   PubMed Web of Science ®Google Scholar
• Sechi E, Buciuc M, Pittock SJ, et al. Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing. JAMA Neurol. 2021;78(6):741–746.
   PubMed Web of Science ®Google Scholar
• Mealy MA, Wingerchuk DM, Greenberg BM, et al. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176–1180.
   PubMedGoogle Scholar
• Flanagan EP, Cabre P, Weinshenker BG, et al. Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016;79(5):775–783.
   PubMed Web of Science ®Google Scholar
• Hor JY, Asgari N, Nakashima I, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 2020;11:501.
   PubMed Web of Science ®Google Scholar
• Weinshenker BG. Neuromyelitis optica is distinct from multiple sclerosis. Arch Neurol. 2007;64(6):899–901.
   PubMedGoogle Scholar
• Wingerchuk D, Pittock S, Lucchinetti C, et al. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007;68(8):603–605.
   PubMed Web of Science ®Google Scholar
• Yu HH, Qin C, Zhang SQ, et al. Efficacy of plasma exchange in acute attacks of neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. J Neuroimmunol. 2020 Nov 20;350:577449.
   PubMed Web of Science ®Google Scholar
• Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019 Nov 28;381(22):2114–2124. ••This paper describes the initial pivotal trial of satralizumab in NMOSD, SAkuraSKY, which compared satralizumab in combination with patients’ baseline immunotherapy with baseline immunotherapy only.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Fujihara K, Palace J, et al. Eculizumab monotherapy for NMOSD: data from PREVENT and its open-label extension. Mult Scler. 2021 Sep 09;480–486.
   PubMed Web of Science ®Google Scholar
• Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352–1363. ••This paper describes the initial pivotal trial of inebilizumab in NMOSD, N-MOmentum, which compared satralizumab in combination with patients’ baseline immunotherapy with baseline immunotherapy only.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614–625. ••This paper describes the pivotal trial that established the efficacy of eculizumab in AQP4 IgG-positive NMOSD. This trial, PREVENT, compared eculizumab (with background immunotherapy permitted) to placebo (with background immunotherapy permitted) and analyzed the time to relapse across groups.
   PubMed Web of Science ®Google Scholar
• D’Amico E, Zanghì A, Chisari CG, et al. Effectiveness and safety of rituximab in demyelinating diseases spectrum: an Italian experience. Mult Scler Relat Disord. 2019;27:324–326.
   PubMed Web of Science ®Google Scholar
• Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(4):298–306. ••This paper describes the clinical trial of rituximab in NMOSD, RIN-1, which compared rituximab to placebo, with a background steroid taper included in both groups.
   PubMed Web of Science ®Google Scholar
• Wallach AI, Tremblay M, Kister I. Advances in the treatment of neuromyelitis optica spectrum disorder. Neurol Clin. 2021. 02. 39(1):35–49.
   PubMed Web of Science ®Google Scholar
• Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021. 01. 20(1):60–67.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Zekeridou A, Weinshenker BG. Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials. Nat Rev Neurol. 2021. 17(12): 759–773. Oct, 28.
   PubMed Web of Science ®Google Scholar
• Abboud H, Salazar-Camelo A, George N, et al. Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders. J Neurol. 2021;17:1–16.
   Google Scholar
• Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood J Am Soc Hematol. 1997;90(6):2188–2195.
   Google Scholar
• Sechi E, Zarbo R, Biancu MA, et al. Prolonged B-cell depletion after rituximab in AQP4-IgG-positive neuromyelitis optica spectrum disorder. J Neuroimmunol. 2021;358:577666.
   PubMed Web of Science ®Google Scholar
• Prescribing information: rituxan (rituximab) [package insert]. South San Francisco CA: Biogen Idec Inc. and Genentech, Inc.; Oct. 2010. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf. Accessed 2022 Aug 24
   Google Scholar
• Kim S-H, Kim W, Li XF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011;68(11):1412–1420.
   PubMedGoogle Scholar
• Avouac A, Maarouf A, Stellmann J-P, et al. Rituximab-induced hypogammaglobulinemia and infections in AQP4 and MOG antibody–associated diseases. Neurol-Neuroimmunol Neuroinflammation. 2021;8(3). •This study investigated infections and hypogammaglobulinemia in Rituximab). •This study investigated infections and hypogammaglobulinemia in Rituximabtreated patients with NMOSD.
   PubMed Web of Science ®Google Scholar
• Marcinnò A, Marnetto F, Valentino P, et al. Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol-Neuroimmunol Neuroinflammation. 2018;5(6):1–7.
   Web of Science ®Google Scholar
• Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402–412. •This paper describes the trial of satralizumab in NMOSD, SAkuraStar, which established the efficacy of satralizumab monotherapy compared to placebo for reduction of NMOSD-related relapses.
   PubMed Web of Science ®Google Scholar
• Duchow A, Bellmann-Strobl J. Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Neurodegener Dis Manag. 2021. 02. 11(1):49–59.
   PubMed Web of Science ®Google Scholar
• Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012 Jun;135(Pt 6):1834–1849.
   PubMedGoogle Scholar
• Holroyd K, Vogel A, Lynch K, et al. Neuromyelitis optica testing and treatment: availability and affordability in 60 countries. Mult Scler Relat Disord. 2019;33:44–50.
   PubMed Web of Science ®Google Scholar
• Espiritu AI, Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Mult Scler Relat Disord. 2019;33:22–32.
   PubMed Web of Science ®Google Scholar
• Chen H, Qiu W, Zhang Q, et al. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. Eur J Neurol. 2017;24(1):219–226.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang Q, H-t R, et al. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: a prospective cohort study. J Neurol Sci. 2016;370:224–228.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang M, Qiu W, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391–401.
   PubMed Web of Science ®Google Scholar
• Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord. 2012;1(4):180–187.
   PubMed Web of Science ®Google Scholar
• Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71(3):324–330.
   PubMed Web of Science ®Google Scholar
• Nazi I, Kelton JG, Larché M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood J Am Soc Hematol. 2013;122(11):1946–1953.
   Google Scholar
• Bingham IIICO, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62(1):64–74.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825–2833.
   PubMed Web of Science ®Google Scholar
• Prescribing information: uplinza (inebilizumab) [package insert]. cited 2022 Aug 28, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761142s000lbl.pdf
   Google Scholar
• Besada E, Koldingsnes W, Nossent JC. Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. Rheumatology. 2014;53(10):1818–1824.
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheumatism. 2010;62(9):2625–2632.
   PubMed Web of Science ®Google Scholar
• Rensel M, Zabeti A, Mealy MA, et al. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial. Mult Scler J. 2021; 925–932;135245852110472.
   Google Scholar
• Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leukemia. 2013;13(2):106–111.
   PubMed Web of Science ®Google Scholar
• Kado R, Sanders G, McCune WJ. Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy. Curr Opin Rheumatol. 2017;29(3):228–233.
   PubMed Web of Science ®Google Scholar
• Tieu J, Smith RM, Gopaluni S, et al. Rituximab associated hypogammaglobulinemia in autoimmune disease. Front Immunol. 2021;12:671503.
   PubMed Web of Science ®Google Scholar
• Kong F, Wang J, Zheng H, et al. Monoclonal antibody therapy in neuromyelitis optica spectrum disorders: a meta-analysis of randomized control trials. Front Pharmacol. 2021;12:652759.
   PubMed Web of Science ®Google Scholar
• Levy M, Berthele A, Kim HJ, et al. Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings From the Phase 3 PREVENT study (1788). AAN Enterprises; 2020.
   Google Scholar
• Brod SA. Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects. Mult Scler Relat Disord. 2020 Nov;46:102538.
   PubMed Web of Science ®Google Scholar
• Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020. MMWR Recommendations Rep. 2020;69(9):1.
   PubMed Web of Science ®Google Scholar
• Food, Administration D Genentech. Rituxan prescribing information. U.S. Food and Drug Administration website. 2019.
   Google Scholar
• Flanagan EP, Levy M, Katz E, et al. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum study. Mult Scler Relat Disord. 2022;57:103352.
   PubMed Web of Science ®Google Scholar
• Sfikakis P, Boletis J, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down‐regulation of the T cell costimulatory molecule CD40 ligand: an open‐label trial. Arthritis Rheum. 2005;52(2):501–513.
   PubMedGoogle Scholar
• Favas C, Isenberg DA. B-cell-depletion therapy in SLE—what are the current prospects for its acceptance? Nat Rev Rheumatol. 2009;5(12):711–716.
   PubMed Web of Science ®Google Scholar
• Prescribing Information: Soliris (eculizumab) [package insert]. cited 2022 Aug 28, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125166s431lbl.pdf
   Google Scholar
• Avasarala J, Sokola BS, Mullins S. Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder. CNS Spectr. 2021;26(3):185–187.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Weitz I, Howard JF, et al. Response to: eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder. CNS Spectr. 2021;26(3):195–196.
   PubMed Web of Science ®Google Scholar
• Chapman P. Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder.
   Google Scholar
• Prescribing information: enspryng (satralizumab) [package insert]. cited 2022 Aug 24, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761149s000lbl.pdf
   Google Scholar
• Lee W-J, Lee S-T, Shin Y-W, et al. Teratoma removal, steroid, IVIG, rituximab and tocilizumab (T-SIRT) in anti-NMDAR encephalitis. Neurotherapeutics. 2021;18(1):474–487.
   PubMed Web of Science ®Google Scholar
• El Afifi AM, Saeed AM, Fekry GH, et al. Successful management of severe hyperhaemolysis with combined tocilizumab and rituximab in non-transfusion-dependent thalassaemia: a case report. Transfusion Med Hemotherapy. 2022;1–5.
   Web of Science ®Google Scholar
• Traboulsee A, Fujihara K, Kim HJ, et al. SAkuraBONSAI: a prospective, open-label study of satralizumab investigating novel imaging, biomarker, and clinical outcomes in patients with aquaporin-4-IgG-seropositive (P15. AQP4-IgG+) NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)(P15-1.002). AAN Enterprises; 2022.
   Google Scholar
• Kim S-H, Jang H, Park NY, et al. Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with aquaporin-4 antibodies. Neurol Neuroimmunol Neuroinflammat. 2021;8(2):e947.
   PubMed Web of Science ®Google Scholar
• Hartung H-P, Meuth SG, Miller DM, et al. Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis. Curr Opin Neurol. 2021;34(4):598–603.
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Hofstadt-van Oy U, Angstwurm K, et al. Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. J Neurol. 2015;262(5):1379–1384.
   PubMed Web of Science ®Google Scholar
• Hyun J-W, Kim G, Kim Y, et al. Severe relapse after cessation of immunosuppressive therapy in a patient with neuromyelitis optica spectrum disorder. Neurologist. 2016;21(6):97–98.
   PubMed Web of Science ®Google Scholar
• Weinfurtner K, Graves J, Ness J, et al. Prolonged remission in neuromyelitis optica following cessation of rituximab treatment. J Child Neurol. 2015;30(10):1366–1370.
   PubMed Web of Science ®Google Scholar
• D’Souza R, Wuebbolt D, Andrejevic K, et al. Pregnancy and neuromyelitis optica spectrum disorder–reciprocal effects and practical recommendations: a systematic review. Front Neurol. 2020;11:1166.
   Web of Science ®Google Scholar
• Kim W, Kim S-H, Nakashima I, et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology. 2012;78(16):1264–1267.
   PubMed Web of Science ®Google Scholar
• Nour MM, Nakashima I, Coutinho E, et al. Pregnancy outcomes in aquaporin-4–positive neuromyelitis optica spectrum disorder. Neurology. 2016;86(1):79–87.
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Hoechsmann B, Szer J, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373(11):1032–1039.
   PubMed Web of Science ®Google Scholar
• Das G, Damotte V, Gelfand JM, et al. Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm. 2018 Mar 19;5(3):e453.
   PubMed Web of Science ®Google Scholar
• Natekar A, Pupco A, Bozzo P, et al. Safety of azathioprine use during pregnancy. Can Fam Physician. 2011 Dec;57(12):1401–1402.
   PubMed Web of Science ®Google Scholar
• Lloyd ME, Carr M, Mcelhatton P, et al. The effects of methotrexate on pregnancy, fertility and lactation. Qjm. 1999 Oct;92(10):551–563.
   PubMed Web of Science ®Google Scholar
• Pisoni CN, D’Cruz DP. The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf. 2008 May;7(3):219–222.
   PubMed Web of Science ®Google Scholar
• Hoeltzenbein M, Beck E, Rajwanshi R, et al. Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data. Semin Arthritis Rheum. 2016 Oct;46(2):238–245.
   PubMed Web of Science ®Google Scholar
• Bragnes Y, Boshuizen R, de Vries A, et al. Low level of Rituximab in human breast milk in a patient treated during lactation. Rheumatology. 2017;56(6):1047–1048.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology. 2020;95(14):e1999–e2008.
   PubMed Web of Science ®Google Scholar
• Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012835.
   Web of Science ®Google Scholar
• Novak F, Nilsson AC, Nielsen C, et al. Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis. Mult Scler Relat Disord. 2021;56:103251.
   PubMed Web of Science ®Google Scholar
• Sabatino JJJ, Mittl K, Rowles WM, et al. Multiple sclerosis therapies differentially impact SARS-CoV-2 vaccine-induced antibody and T cell immunity and function. JCI Insight. 2022;7:1–15 .
   Web of Science ®Google Scholar
• Habek M, Željko C, Mlakar AS, et al. Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: effects of disease modifying therapies. Mult Scler Relat Disord. 2022;362:103682.
   Google Scholar
• Abboud H, Zheng C, Kar I, et al. Current and emerging therapeutics for neuromyelitis optica spectrum disorder: relevance to the COVID-19 pandemic. Mult Scler Relat Disord. 2020;44:102249.
   PubMed Web of Science ®Google Scholar
• Cai H, Zhou R, Jiang F, et al. Vaccination in neuromyelitis optica spectrum disorders: friend or enemy? Mult Scler Relat Disord. 2021;58:103394.
   PubMed Web of Science ®Google Scholar
• Zrzavy T, Wimmer I, Rommer PS, et al. Immunology of COVID‐19 and disease‐modifying therapies: the good, the bad and the unknown. Eur J Neurol. 2021;28(10):3503–3516.
   PubMed Web of Science ®Google Scholar
• Bingham CO, Rizzo W, Kivitz A, et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2015;74(5):818–822.
   PubMed Web of Science ®Google Scholar
• Marignier R, Pittock SJ, Paul F, et al. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2021;57. [2021 Nov 01];103356.
   PubMed Web of Science ®Google Scholar
• Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5(12):1731–1740.
   PubMed Web of Science ®Google Scholar
• Lotan I, McGowan R, Levy M. Anti-IL-6 therapies for neuromyelitis optica spectrum disorders: a systematic review of safety and efficacy. Curr Neuropharmacol. 2021;19(2):220–232.
   PubMed Web of Science ®Google Scholar
• Lotan I, Charlson RW, Ryerson LZ, et al. Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2020;39:101920.
   PubMed Web of Science ®Google Scholar
• Ringelstein M, Ayzenberg I, Lindenblatt G, et al. Interleukin-6 receptor blockade in treatment-refractory MOG-IgG–associated disease and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflammat. 2022;9(1):e1100.
   PubMed Web of Science ®Google Scholar
• Yong KP, Kim HJ. Demystifying MOGAD and double seronegative NMOSD further with IL-6 blockade. Neurol Neuroimmunol Neuroinflammat. 2022;9(1):e1110.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang C, Bai P, et al. Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study. Acta Neurol Belg. 2017;117(3):695–702.
   PubMed Web of Science ®Google Scholar
• Lin J, Li X, Xue B, et al. Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder. J Neuroimmunol. 2018;317:1–4.
   PubMed Web of Science ®Google Scholar
• Huang W, Wang L, Xia J, et al. Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder. Eur J Neurol. 2022;29:2343–2354.
   PubMed Web of Science ®Google Scholar
• Marignier R, Bennett JL, Kim HJ, et al. Disability outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2021 05;8(3):1–13.
   Web of Science ®Google Scholar